Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0927 • ACR Convergence 2022
Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
Nehad Soloman¹, Kent Kwas Huston², Jasvinder singh³, Simon Helfgott⁴, Andrew Frick⁵, Scott Milligan⁵ and Colin Edgerton⁶, ¹Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ²Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Trio Health, Louisville, CO, ⁶Articularis Healthcare, Sullivans Island, SC
Background/Purpose: Treatment efficacy for rheumatoid arthritis is often measured through disease assessments containing subjective input from the provider, the patient, or both. Here we compare…
Abstract Number: 1094 • ACR Convergence 2022
Mechanical Loading-induced BHLHE40 Promotes Inflammatory Arthritis
Eric Gracey¹, Carolien Vlieghe², Isabelle Cambre¹, Elisabeth Gilis¹, Flore Stappers³, Guillaume Planckaert¹, Rik Lories⁴, Aline Bozec⁵ and Dirk Elewaut⁶, ¹Ghent University, Gent, Belgium, ²VIB-UGent Center for Inflammation Research, Ghent University, Belgium, Gent, Belgium, ³VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium, ⁴KU Leuven, Leuven, Belgium, ⁵Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium
Background/Purpose: Force induced microdamage to joint tissue is hypothesized to trigger inflammatory events in the joint leading to arthritis. Patients with inflammatory arthritis, such as…
Abstract Number: 1210 • ACR Convergence 2022
Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
Namrata Singh¹, Alexander Peterson², Aaron Baraff², Ajay Gopal³, Nicholas Smith⁴, Jennifer Barton⁵, Jeffrey Curtis⁶ and Noel Weiss³, ¹University of Washington, Bellevue, WA, ²VA Puget Sound, SEATTLE, WA, ³University of Washington, Seattle, WA, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Epidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) are associated with lymphoma development [1]. Whether the decrease…
Abstract Number: 1333 • ACR Convergence 2022
Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry
William Nowell¹, Shilpa Venkatachalam², Kelly Gavigan¹, Michael George³, Johanna Withers⁴, Laura Stradford⁵, Esteban Rivera¹ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Scipher Medicine Corportaion, Waltham, MA, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Although patients' (pts) perspective on disease-related lab testing and its role in treatment decision-making has been examined for some chronic illnesses, ranging from diabetes…
Abstract Number: 1395 • ACR Convergence 2022
Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis
Yao-Fan Fang¹ and Lai-Chu See², ¹Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan, Taiwan
Background/Purpose: Since 2010, biological disease-modifying antirheumatic drugs (bDMARDs) have been the dominant mode of treatment for rheumatoid arthritis (RA). However, the safety of DMARDs, such…
Abstract Number: 1411 • ACR Convergence 2022
Predictors of Achieving Clinical Remission in ACPA-positive RA-patients Treated with Abatacept and Methotrexate or Methotrexate Monotherapy
Marloes Verstappen¹, Ellis Niemantsverdriet², Tom Huizinga¹, Annette van der Helm-van Mil³ and Sytske Anne Bergstra², ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: With a wide range of disease modifying treatment available, clinical remission is frequently achieved in rheumatoid arthritis (RA). Although a proportion of RA-patients achieves…
Abstract Number: 1430 • ACR Convergence 2022
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Cristiano Moura¹, Luck Lukusa¹, Laura Yan¹, Walter P Maksymowych², Denis Choquette³, Gilles Boire⁴ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
Abstract Number: 1605 • ACR Convergence 2022
Profound Anticoagulant Effects of Initial Antirheumatic Treatments in Early Rheumatoid Arthritis Patients; A NORD-STAR Spin-off Study
Bas Dijkshoorn¹, Daisy Vedder¹, Anna Rudin², Dan Nordstrom³, Bjorn Gudbjornsson⁴, Kristina Lend⁵, Till Uhlig⁶, Espen Haavardsholm⁶, Gerdur Maria Grondal⁷, Merete L Hetland⁸, Marte Heiberg⁶, Mikkel Østergaard⁹, Kim Horslev-Petersen¹⁰, Jon Lampa¹¹, Ronald van Vollenhoven¹², Aleksandra antovic¹³ and Michael Nurmohamed¹⁴, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ³Helsinki University Hospital, Helsinki, Finland, ⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁵The Karolinska Institute, Stockholm, Sweden, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Landspitali University Hospital, Centre for Rheumatology Research, Reykjavik, Iceland, ⁸Rigshospitalet, Glostrup, Denmark, ⁹Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ¹⁰Danish Hospital for Rheumatic Diseases, Haderslev, Denmark, ¹¹Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Karolinska Institute, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹⁴Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of venous thromboembolism. Thus far, there have not been any comparative studies investigating the…
Abstract Number: 1699 • ACR Convergence 2022
Arthritis-associated Synovial CD64-Ly6c- myeloid Cells Comprise 2 Subpopulations
Yidan Wang¹, Miranda Gurra¹, Carla Cuda¹, Hadijat Makinde¹, Shangyang Chen¹, Gaurav Gadhvi¹, Salina Dominguez¹, Caroline Shah¹, Deborah Winter² and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Skokie, IL
Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of circulating monocytes – either classical or non-classical monocytes – is not…
Abstract Number: 1760 • ACR Convergence 2022
Diagnoses Rates in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients During COVID-19
W. Cliff Rutter, Will Cavers, Jean Park, Elisea Avalos-Reyes and Kjel Johnson, CVS Health, Lincoln, RI
Background/Purpose: COVID-19 is of particular concern to patients with autoimmune rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE).…
Abstract Number: 1954 • ACR Convergence 2022
Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews
Simon Helfgott¹, Kent Kwas Huston², Jasvinder singh³, Nehad Soloman⁴, Jeremy Broestl⁵, Kimmi Cox⁵, Kelsey Milligan⁵ and Colin Edgerton⁶, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁵Trio Health, Louisville, CO, ⁶Articularis Healthcare, Sullivans Island, SC
Background/Purpose: Clinical and non-clinical forces contribute to real-world treatment effectiveness, yet most studies focus on efficacy in an idealized setting. To identify factors impacting clinical…
Abstract Number: 1971 • ACR Convergence 2022
Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment
Sascha Heckert¹, Sytske Anne Bergstra², Yvonne Goekoop-Ruiterman³, Melek Guler-Yuksel⁴, Willem Lems⁵, Xanthe Matthijssen⁶, Maikel Van Oosterhout⁷, Tom Huizinga⁶ and CF Allaart⁶, ¹Leiden University Medical Centre, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³HagaZiekenhuis, The Hague, Netherlands, ⁴Maasstad ziekenhuis, Rotterdam, Netherlands, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Groene Hart Ziekenhuis, Gouda, Netherlands
Background/Purpose: In Rheumatoid Arthritis (RA), both systemic and local disease activity have been shown to be associated with joint damage progression. Earlier we showed that…
Abstract Number: 1989 • ACR Convergence 2022
Predictors of Flare in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
Nada Alrifai¹, Mohamed Tageldin², Malavikalakshmi Attur², Nicholas Wilson², Rebecca schorr² and Tarun Sharma², ¹Allegheny Health Network, Pittsburgh, ²Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Long term use of conventional synthetic DMARDs (csDMARDs) and biologics in RA has clinical risks including infection and malignancy. Few RCTs and real-world studies…
Abstract Number: 2005 • ACR Convergence 2022
Comparison of Treatment and Disease Activity in the Early Stage of Onset in Patients with Elderly-onset vs Younger-onset Rheumatoid Arthritis Using Data of National Database of Rheumatic Diseases in Japan (NinJa)
Toshihiro Matsui¹ and Shigeto Tohma², ¹NHO Sagamihara National Hospital, Kanagawa, Japan, ²National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: To clarify the current status and issues concerning treatment in the early stage of onset in patients with elderly-onset rheumatoid arthritis (RA) in Japan.Methods:…
Abstract Number: 2185 • ACR Convergence 2022
Development of a Novel Regulatory T Cell-Based Therapy for Patients with Rheumatoid Arthritis
Anne-Renee van der Vuurst de Vries¹, Kathryn Hooper¹, Jonathan Graf², Katie Tuckwell¹ and Joshua Beilke¹, ¹Sonoma Biotherapeutics, South San Francisco, CA, ²Ucsf, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory condition with persistent unmet medical need despite significant treatment advances. The pathogenesis of RA is initiated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].